Breaking! COVID-19-Drugs: Gilead’s Experimental Drug Remdesivir Fails In China’s Clinical Trials
Source: COVID-19 Drugs Apr 24, 2020 3 years, 11 months, 3 weeks, 4 days, 14 hours, 36 minutes ago
COVID-19 Drugs: Media reports are emerging everywhere that not only has Gilead’s Remidesivir Clinical Trial in China failed but also there could be the possibility of a cover-up and future data being manipulated as a result of the Giant Pharma company’s extensive financial resources.
Reports are emerging that the experimental antiviral drug Remdesivir has failed in its first randomized clinical trial to treat the COVID-19 illness according to reports that were quoting draft documents that were accidentally published by the World Health Organization.
However, Gilead Sciences, the company behind the medicine, disputed how the now deleted post had characterized the findings, saying the data showed a "potential benefit."
Various media reported that researchers in China carried out a study on 237 patients, giving the drug to 158 and comparing their progress with a control group of 79.
According to a summary of the experiment, Remdesivir was "not associated with a difference in time to clinical improvement" compared to the control. Use of the drug was not associated with patients getting better, faster. And 13.9 per cent of patients getting the drug died, versus 12.8 per cent getting standard care.
Please, we desperately need your kind help! Please help support our site and our initiatives to propel and aid research by making a donation to help sustain the site. We are also trying to raise funds to help poor undocumented refugees who have no access to public healthcare during the COVID-19 crisis. Donations are accepted via paypal: https://www.thailandmedical.news/p/sponsorship
A PR spokesman for Gilead told media, "We believe the post included inappropriate characterizations of the study," saying it was terminated early due to low enrollment and was therefore not statistically meaningful.
He added, "As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease."
The clinical trial does not represent the final word on the matter and there are several large-scale trials in advanced stages that should soon provide a clearer picture.
The antiviral Remdesivir, which is administered intravenously, was among the first drugs mooted as a treatment for the novel coronavirus and as such has great hopes riding on it.
The drug, Remdesivir belongs to a class of drugs that act on the virus directly as opposed to controlling the abnormal and often lethal autoimmune response it causes. It mimics one of the four building blocks of RNA and DNA and gets absorbed into the virus's genome, which in turn stops the pathogen from replicating.
However the drug is highly toxic and many medical experts were already warning against its use in the early days during the outbreak as severe or critically infected COVID-19 patients we
re found to have died from using it.
Also many doctors are warning that all clinical trials conducted or indirectly influenced by the big pharmaceutical entities should be watched with extreme caution as they are only profit orientated.
For the latest on
COVID-19 drugs, keep on logging to
Thailand Medical News
Please, we desperately need your kind help! Please help support our site and our initiatives to propel and aid research by making a donation to help sustain the site. We are also trying to raise funds to help poor undocumented refugees who have no access to public healthcare during the COVID-19 crisis. Donations are accepted via paypal: https://www.thailandmedical.news/p/sponsorship
